Navigation Links
Scientific Presentations at 2011 AAPM/COMP Meeting Highlight TrueBeam® and RapidArc® Radiotherapy Systems From Varian Medical Systems
Date:8/9/2011

VANCOUVER, British Columbia, Aug. 9, 2011 /PRNewswire/ -- Medical physicists researching RapidArc® radiotherapy technology from Varian Medical Systems (NYSE: VAR) have reported that, compared with conventional approaches to radiotherapy, RapidArc treatment plans for lung, abdominal and spinal tumors do a better job of sparing healthy tissues and organs.

Presenting at a professional conference of medical physicists last week, a team from Mount Sinai Medical Center in New York reported that a RapidArc treatment plan for treating a single complex case of lung cancer spared more healthy tissues and critical organs than a treatment plan for IMRT or 3-D conformal radiotherapy.  In this treatment plan comparison study, the average dose to healthy lung tissues was 8 Gy lower for the RapidArc plan as compared with the other two treatment approaches. The amount of healthy tissue receiving 10-20% of the prescribed dose—a common way of measuring how much healthy tissue is being impacted—was 45% to 50% lower for the RapidArc plan, compared to the other two plan types.  In addition, the investigators found the RapidArc plan offered better tumor coverage than the 3-D conformal radiotherapy plan.(1)

"RapidArc for whole abdominal irradiation in patients offers better homogeneity with the same level of kidney sparing while providing more sparing of organs at risk, such as the bone marrow," concluded a team of researchers from North Shore Long Island Jewish Health System, in a poster presentation comparing RapidArc with a more conventional 2-beam approach to whole abdominal radiotherapy for a single patient.  For example, the amount of healthy bone marrow receiving up to 90% of the prescribed dose went from 95.13% with the conventional treatment plan down to 18.4% in the RapidArc plan.(2) Whole abdominal radiotherapy is often prescribed for some gynecological and gastrointestinal cancers.

Clinicians from St. Luke's Hospital in Bethlehem, Pennsylvania, described an approach to RapidArc treatment planning that enabled them to achieve superior dose distributions for treating spine tumors with stereotactic radiosurgery.  Their poster presentation studied the dosimetry characteristics of 11 RapidArc treatment plans for spinal tumors, and concluded that their RapidArc plans "allow for extremely rapid dose fall off," which means that outside the target area, the dose levels drop very quickly to help protect surrounding healthy tissues.(3)

RapidArc delivers a precise and efficient treatment in a single or multiple arcs of the treatment machine around the patient and makes it possible to deliver image-guided radiotherapy treatments two to eight times faster than is possible with conventional approaches such as fixed-field IMRT or 3-D conformal radiotherapy.

The scientific program at the 2011 joint meeting of the American Association of Physicists in Medicine (AAPM) and the Canadian Organization of Medical Physicists (COMP) included other notable presentations and posters:

  • Researchers from Memorial Sloan-Kettering Cancer Center in New York presented about a method they developed for imaging patients during RapidArc treatments, using the imager on Varian's TrueBeam system to facilitate real-time image guidance. (4)*
  • A team from Vanderbilt University Medical Center in Nashville, Tennessee, conducted measurement studies to verify that the TrueBeam system's imager can produce 3-D (cone-beam CT) images using less X-ray dose than earlier generations of technology, without compromising image quality.(5),*
  • Stanford University researchers reported on a quality assurance (QA) method for gated RapidArc treatments designed to compensate for respiratory motion during stereotactic body radiotherapy treatments.  They simulated imaging, treatment planning, and treatment delivery using a moving phantom to verify that gated RapidArc can produce dose distributions that accurately conform to the three-dimensional shape of a targeted tumor even though dose delivery is continually adjusted to compensate for tumor motion during treatment. (6)
  • Three research teams reported on the Acuros XB dose calculation algorithm, which was added to Varian's Eclipse™ treatment planning software last year as a faster alternative to Monte Carlo algorithms for planning RapidArc and other complex treatments. A group from the M.D. Anderson Cancer Center in Houston reported on a head and neck cancer case that was planned using diverse calculation algorithms that were then compared.  They concluded that the Acuros XB algorithm makes it possible to complete calculations for a RapidArc treatment plan roughly three times faster than the AAA algorithm.(7) Another M. D. Anderson team used a phantom study to compare the dosimetric performance of Acuros XB with other treatment planning algorithms.  Acuros XB was found to be equivalent to the Monte Carlo (MC) algorithm and superior to the anisotropic analytical algorithm (AAA) and the collapsed-cone convolution (CCC) algorithm.(8)  And a group from the Istituto Oncologico della Svizzera Italiana (IOSI) in Bellinzona, Switzerland performed a treatment planning and phantom irradiation study to validate Acuros XB as a viable algorithm for planning RapidArc stereotactic treatments.(9)*

"Over 50 presentations and posters at this year's international meeting of medical physicists reported on clinical or scientific work using Varian technology," said Chris Toth, senior director of marketing for Varian's Oncology Systems business.  "Of those, 35 were based on our RapidArc radiotherapy technology, while another eleven looked at ways of using our TrueBeam system for image-guided radiotherapy and radiosurgery.  We're gratified to see so many leading clinical researchers using Varian technology to advance the field of radiation oncology."

Varian high-energy linear accelerators, including the TrueBeam™ machine, have been cleared by the FDA for treating lesions, tumors, and conditions anywhere in the body when radiation treatment is indicated.  Eclipse treatment planning software has been cleared for planning photon, electron, and proton beam radiotherapy for patients with malignant or benign diseases.

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.

*One or more members of this research team received research grant support from Varian Medical Systems.

FOR INFORMATION CONTACT:
Meryl Ginsberg
Tel: 650.424.6444
meryl.ginsberg@varian.com

(1) Dumane V et al.  Comparison of Rapidarc, IMRT and 3D Conformal Planning for Treatment of Chestwall, and Regional Nodes. Abstract of poster presented at the 2011 Joint meeting of the American Association of Physicists in Medicine (AAPM) and the Canadian Organization of Medical Physicists (COMP), Sunday, July 31, 2011.

(2) Yuen P et al. Phantom and clinical study of whole-abdominal radiation therapy on a TrueBeam linac: a comparison between traditional treatment and volumetric intensity–modulated arc therapy.  Abstract of poster presented at the 2011 Joint meeting of the American Association of Physicists in Medicine (AAPM) and the Canadian Organization of Medical Physicists (COMP), Sunday, July 31, 2011.

(3) Song X et al.  A Study of RapidArc SBRT Spine Treatment Plans. Abstract of poster presented at the 2011 Joint meeting of the American Association of Physicists in Medicine (AAPM) and the Canadian Organization of Medical Physicists (COMP), Sunday, July 31, 2011.

(4) Ling C et al. Concomitant RapidArc® and Acquisition of KV-CBCT with Minimal MV Scatter.  Abstract for a presentation at the 2011 Joint meeting of the American Association of Physicists in Medicine (AAPM) and the Canadian Organization of Medical Physicists (COMP), Monday, August 01, 2011.

(5) Ding G et al.  Reduced CBCT Imaging Dose Due to the New X-Ray Source in TrueBeam.  Abstract for a presentation at the 2011 Joint meeting of the American Association of Physicists in Medicine (AAPM) and the Canadian Organization of Medical Physicists (COMP), Sunday, July 31, 2011.

(6) Hsu A et al.  Quality Assurance of Gated RapidArc Stereotactic Body Irradiation.   Abstract for a presentation at the 2011 Joint meeting of the American Association of Physicists in Medicine (AAPM) and the Canadian Organization of Medical Physicists (COMP), Sunday, July 31, 2011.

(7) Han T et al. Dosimetric Verification of Deterministic Acuros XB Radiation Transport Algorithm for IMRT and VMAT Plans with the RPC H&N Phantom.  Abstract of poster presented at the 2011 Joint meeting of the American Association of Physicists in Medicine (AAPM) and the Canadian Organization of Medical Physicists (COMP), Sunday, July 31, 2011.

(8) Han T et al. Dosimetric Comparison of Acuros XB Deterministic Radiation Transport Method with Monte Carlo and Model-Based Convolution Methods in Heterogeneous Media. Abstract for a presentation at the 2011 Joint meeting of the American Association of Physicists in Medicine (AAPM) and the Canadian Organization of Medical Physicists (COMP), Monday, August 01, 2011.

(9) Fogliata A. Acuros XB and AAA Dose Calculation Accuracy for Small Fields in RapidArc Treatments. Abstract of poster presented at the 2011 Joint meeting of the American Association of Physicists in Medicine (AAPM) and the Canadian Organization of Medical Physicists (COMP), Sunday, July 31, 2011.


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
3. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
10. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
11. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):